Busadre, Joy D.
HRN: 01-18-25 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/23/2023
CEFTAZIDIME 1GM (VIAL)
11/23/2023
11/29/2023
IV
1 Gram
Q 8 Hours
Carcinoma Breast
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes